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Abstract
The study conducted by Seligman and coworkers included in the
previous issue of Critical Care demonstrates that copeptin is a
promising marker to predict outcome in patients with ventilator-
associated pneumonia. In recent years, copeptin has emerged as a
new prognostic marker in a variety of diseases, such as sepsis,
community-acquired pneumonia, chronic obstructive pulmonary
failure, heart failure and myocardial infarction. What is the patho-
physiological basis for these findings? Copeptin together with
vasopressin is co- secreted from the posterior pituitary and there-
fore mirrors the amount of vasopressin in the circulation. Vaso-
pressin is a main secretagogue of the hypothalamo–pituitary–
adrenal axis, thereby mirroring the individual stress level. Further-
more, vasopressin is an important hormone in salt and volume
regulation. In this context, copeptin is also a diagnostic marker in
patients with diabetes insipidus and in patients with disordered
water states.
In the previous issue of Critical Care, Seligman and
coworkers showed that copeptin, the C-terminal part of the
vasopressin prohormone, increased continuously with the
severity of sepsis [1]. Copeptin remained the only accurate
prognostic marker for mortality in patients with ventilator-
associated pneumonia. Procalcitonin and the PaO2/FiO2
ratio, shown to be prognostic in ventilator-associated
pneumonia [2], unfortunately were not included in the
analysis. Nevertheless, the authors conclude that copeptin
could be useful in risk-stratifying patients with ventilator-
associated pneumonia and may provide an early indication of
treatment failure.
The severity of a disease influences the consumption of
costly healthcare resources, including the need for intensive
care admission and the suitability for discharge, among
others. An early and adequate prognosis and risk assessment
facilitates an optimized care of patients with severe infections
and other compromising diseases. In this context, there is a
potential need for readily measurable biomarkers to predict
disease severity and, finally, outcome. The advantage of
biomarkers is that they are rapidly and easily available and are
not investigator dependent.
Copeptin is cosynthesized with vasopressin, also known as
antidiuretic hormone, thereby directly mirroring vasopressin
levels – but copeptin is more stable in plasma and serum [3].
Vasopressin not only has hemodynamic and osmoregulatory
effects but also reflects the individual stress level. Copeptin
shows identical changes during disordered water states as
previously shown for vasopressin [4], and directly correlates
with plasma vasopressin levels in healthy volunteers and
critically ill patients.
In the past 2 years copeptin has been studied as a diagnostic
marker and as a prognostic marker in different diseases. As a
diagnostic marker, copeptin was evaluated in patients with
diabetes insipidus – for example, after pituitary surgery. In
these patients copeptin had a superior diagnostic accuracy
to detect an insufficient activity of the posterior pituitary,
offering an alternative to the laborious and ambiguous water-
deprivation test [5]. As a prognostic marker, copeptin levels
were independent predictors of survival in critically ill patients
suffering from hemorrhagic and septic shock [6]. In lower
respiratory tract infections, the copeptin levels were
significantly higher as compared with control individuals, with
the highest levels in patients with community-acquired
pneumonia [7]. Copeptin levels increased with increasing
severity of pneumonia, as classified by the pneumonia
severity index. Similarly, in patients with acute exacerbations
of chronic obstructive pulmonary disease, copeptin was
shown to be predictive of long-term clinical failure
independent of age, comorbidity, hypoxemia and lung
functional impairment in multivariate analysis [8].
Copeptin levels also have prognostic implications in diseases
other than infections. In patients with destabilized heart
failure, copeptin was an accurate prognostic marker for
Commentary
Copeptin: a new and promising diagnostic and prognostic
marker
Mira Katan, Beat Müller and Mirjam Christ-Crain
Department of Endocrinology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
Corresponding author: Mirjam Christ-Crain, mirjam.christ-crain@unibas.ch
Published: 6 March 2008 Critical Care 2008, 12:117 (doi:10.1186/cc6799)
This article is online at http://ccforum.com/content/12/2/117
© 2008 BioMed Central Ltd
See related research by Seligman et al., http://ccforum.com/content/12/1/R11Page 2 of 2
(page number not for citation purposes)
Critical Care    Vol 12 No 2 Katan et al.
mortality [9,10]. In postacute myocardial infarction cases,
copeptin was elevated in patients who died compared with
survivors. Copeptin was thereby a significant independent
predictor of death or heart failure within 60 days [11].
Why is copeptin a good prognostic tool in a variety of
diseases? Vasopressin, together with corticotropin-releasing
hormone, is the main secretagogue of the hypothalamo–
pituitary–adrenal axis to produce adrenocorticotropic hormone
and cortisol. Serum cortisol levels have been reported to be
proportionate to the degree of stress and, by mirroring the
individual stress level, to predict outcome in sepsis and
pneumonia [12]. Importantly, copeptin levels seem to mirror
even more subtly moderate levels of stress than cortisol levels
[13].
Copeptin analysis may be suitable to answer vital clinical
questions. For the critical care clinician, this analysis could be
particularly helpful in patients where knowledge of endo-
genous vasopressin, mirrored by copeptin concentrations, is
crucial for therapy [14], such as in patients with prolonged
hypotension and ongoing vasopressor drug requirements
[15] or in patients with electrolyte disturbances.
Of course, any biomarkers will always oversimplify the
interpretation of important variables, and therefore biomarkers
are meant to complement, rather than to supersede, the
judgment of clinicians and/or validated clinical severity
scores. Conceptually, the likelihood of an adverse outcome
should determine the medical indication, the length of
hospitalization and the allocation of healthcare resources. It is
time to perform intervention studies using biomarkers such as
copeptin in specific settings to guide the allocation of
hospital resources, including the need for intensive care
admission and duration to ultimately prove their clinical
usefulness and cost-efficiency.
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